阿德福韦酯联合扶正化瘀胶囊治疗慢性乙型病毒性肝炎肝纤维化临床察
 |
| 第1页 |
参见附件。
【摘要】目的探讨阿德福韦酯联合扶正化瘀胶囊对慢性乙型病毒性肝炎肝纤维化指标的影响。方法50例慢性乙型病毒性肝炎患者被随机分为联合治疗组(n=25。阿德福韦酯联合扶正化瘀胶囊)和对照组(砣=25。单用阿德福韦酯)，临床观察48周疗效。结果联合治疗组患者48周后肝纤维化指标下降幅度明显高于对照组(P<0.05)；联合治疗组48周时脾脏厚度恢复正常.门静脉内径明显缩小。与治疗前比较，差异均有显著性意义(P<0.05)；其中48周时联合治疗组与单药治疗组比较，差异有显著性意义(P<0.05)。绪论阿德福韦酯联合扶正化瘀胶囊治疗肝纤维化疗效优于单药阿德福韦酯治疗。
【关键词】阿德福韦酯；扶正化瘀胶囊；肝纤维化；联合治疗
The clinical observation of adefovir dipivoxil combined Fuzhenghuayu capsule treatment of chronic hepatitis B with liver fibrosis
【Absrract】objectiveTo explore the effect of Fuzhenghuayu capsule combined adefovir dipivoxil on liver fibrosis in chronic hepatitis B.Methods Fifty patients with chronic hepatitis B patients were randomly divided into combined treatment group(n=25，adefovir dipivoxil combined Fuzhenghuayu capsule)and the oontroIgroup(n=25，Adefovir dipivoxil alone).CLinical efficacy was observed 48 weeks later.Results After 48 weeks.1iver fibrosis indexs in the treatment group WaS significantly lower than control group(P
您现在查看是摘要介绍页，详见PDF附件(2764kb)。